When a drug appears to be less effective than preclinical models suggest , can failures in effectiveness from delivery or dosing be differentiated? The disappointing results of clinical trials with IL-10 --so at odds with the prediction of benefit from animal models --bring into question the validity of those models as well as the soundness of design of the clinical trials on which efficacy of IL-10 is judged .
when a drug appears to be less effective than preclinical models suggest , can failures in effectiveness from delivery or dosing be differentiated? the disappointing results of clinical trials with il-10 --so at odds with the prediction of benefit from animal models --bring into question the validity of those models as well as the soundness of design of the clinical trials on which efficacy of il-10 is judged .
O O O O O O O O O B-other_name I-other_name O O O O O O O O O O O O O O O O O O O B-protein_molecule O O O O O O O O O B-multi_cell I-multi_cell O O O O O O O O O O O O O O O O O B-other_name I-other_name O O O O B-protein_molecule O O O